Matches in Nanopublications for { ?s ?p "[When KIRs were analyzed in combination with their HLA ligands, the proportion of individuals carrying inhibitory KIR3DL1 and HLA-Bw4 but not activating receptor KIR3DS1, a combination presumed to be the most inhibitory of all KIR3DS1/3DL1/HLA-B combinations, was significantly increased in the MPA group compared with the control group (46.5% versus 27.0%; P = 0.014, OR 2.35, 95% CI 1.18-4.70).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP524916.RACqqPICVk9E2VChtHFSizMcVxL3xQ113hQJXd-IBqrQ0130_assertion description "[When KIRs were analyzed in combination with their HLA ligands, the proportion of individuals carrying inhibitory KIR3DL1 and HLA-Bw4 but not activating receptor KIR3DS1, a combination presumed to be the most inhibitory of all KIR3DS1/3DL1/HLA-B combinations, was significantly increased in the MPA group compared with the control group (46.5% versus 27.0%; P = 0.014, OR 2.35, 95% CI 1.18-4.70).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP524916.RACqqPICVk9E2VChtHFSizMcVxL3xQ113hQJXd-IBqrQ0130_provenance.
- NP451981.RASIY2F8ex4FdJqJeDtcPfDTLuVmmRxLq5BJCT-vRCjOg130_assertion description "[When KIRs were analyzed in combination with their HLA ligands, the proportion of individuals carrying inhibitory KIR3DL1 and HLA-Bw4 but not activating receptor KIR3DS1, a combination presumed to be the most inhibitory of all KIR3DS1/3DL1/HLA-B combinations, was significantly increased in the MPA group compared with the control group (46.5% versus 27.0%; P = 0.014, OR 2.35, 95% CI 1.18-4.70).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451981.RASIY2F8ex4FdJqJeDtcPfDTLuVmmRxLq5BJCT-vRCjOg130_provenance.
- NP538154.RA361FaxByH0BLImKM1Aosb5HRx7ll73eOtwv7pftcWi8130_assertion description "[When KIRs were analyzed in combination with their HLA ligands, the proportion of individuals carrying inhibitory KIR3DL1 and HLA-Bw4 but not activating receptor KIR3DS1, a combination presumed to be the most inhibitory of all KIR3DS1/3DL1/HLA-B combinations, was significantly increased in the MPA group compared with the control group (46.5% versus 27.0%; P = 0.014, OR 2.35, 95% CI 1.18-4.70).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP538154.RA361FaxByH0BLImKM1Aosb5HRx7ll73eOtwv7pftcWi8130_provenance.
- assertion description "[When KIRs were analyzed in combination with their HLA ligands, the proportion of individuals carrying inhibitory KIR3DL1 and HLA-Bw4 but not activating receptor KIR3DS1, a combination presumed to be the most inhibitory of all KIR3DS1/3DL1/HLA-B combinations, was significantly increased in the MPA group compared with the control group (46.5% versus 27.0%; P = 0.014, OR 2.35, 95% CI 1.18-4.70).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[When KIRs were analyzed in combination with their HLA ligands, the proportion of individuals carrying inhibitory KIR3DL1 and HLA-Bw4 but not activating receptor KIR3DS1, a combination presumed to be the most inhibitory of all KIR3DS1/3DL1/HLA-B combinations, was significantly increased in the MPA group compared with the control group (46.5% versus 27.0%; P = 0.014, OR 2.35, 95% CI 1.18-4.70).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP538160.RAFuyN0wfV727sKs3mK_abnjzIvWz3bEZPhJ-eeMQwxHI130_assertion description "[When KIRs were analyzed in combination with their HLA ligands, the proportion of individuals carrying inhibitory KIR3DL1 and HLA-Bw4 but not activating receptor KIR3DS1, a combination presumed to be the most inhibitory of all KIR3DS1/3DL1/HLA-B combinations, was significantly increased in the MPA group compared with the control group (46.5% versus 27.0%; P = 0.014, OR 2.35, 95% CI 1.18-4.70).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP538160.RAFuyN0wfV727sKs3mK_abnjzIvWz3bEZPhJ-eeMQwxHI130_provenance.